SecBot SecBot
PRESS-RELEASE ·Filed Jun 15, 2026

LFCR

Lifecore Biomedical, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

The consistent late-stage program wins (seven in seven months) suggest strong customer demand and revenue visibility for Lifecore's CDMO services. Monitor upcoming quarterly filings for revenue recognition from these contracts and any new customer announcements. The neurology product win adds diversification to the pipeline.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.49
T+0 close · Jun 15, 2026 · via day close
Latest settled
−25.50%
T+60 · $4.09
Vs SPY
−26.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $5.49entry
  2. T+1 · 5mo ago −2.55%α −1.95% · $5.35
  3. T+5 · 5mo ago +0.73%α +2.11% · $5.53
  4. T+20 · 4mo ago −15.66%α −14.91% · $4.63
  5. T+60 · 2mo ago −25.50%α −26.50% · $4.09
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifecore Biomedical announced a new commercial manufacturing agreement with an unnamed global pharmaceutical company for an injectable neurology product. This marks the seventh late-stage program win in seven months, signaling strong business development momentum for the CDMO.

Key Facts

  • New agreement with a global pharma company for tech transfer and commercial manufacturing of an injectable suspension product for neurological disorders
  • Seventh late-stage program win in the last seven months
  • Product is a higher-viscosity suspension formulation requiring specialized manufacturing expertise
  • Contract is with an undisclosed global pharmaceutical company (counterparty name not disclosed)

Financial Impact

Revenue contribution and contract value not disclosed; seven late-stage wins in seven months indicate accelerating commercial pipeline growth

revenuepipeline

Risk Factors

  • Counterparty and deal financial terms undisclosed, making revenue impact unclear
  • Late-stage programs may not all reach commercial launch if customers fail to obtain regulatory approval
  • Customer concentration risk if agreements are with a small number of large pharma partners

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311684

Track record

20 reports on LFCR

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
  2. Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
  3. Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
  4. Nov 4, 202612d ago 8-K Bearish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
  6. Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
  7. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
  8. Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
  9. Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
  10. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026